Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium by Markowski, Dominique N et al.
RESEARCH ARTICLE Open Access
Fibroid explants reveal a higher sensitivity against
MDM2-inhibitor nutlin-3 than matching
myometrium
Dominique N Markowski
1†, Burkhard M Helmke
2†, Arlo Radtke
1, Jennifer Froeb
1, Gazanfer Belge
1,
Sabine Bartnitzke
1, Werner Wosniok
3, Iris Czybulka-Jachertz
4, Ulrich Deichert
5 and Jörn Bullerdiek
1,6*
Abstract
Background: Spontaneous cessation of growth is a frequent finding in uterine fibroids. Increasing evidence
suggests an important role of cellular senescence in this growth control. Deciphering the underlying mechanisms
of growth control that can be expected not only to shed light on the biology of the tumors but also to identify
novel therapeutic targets.
Methods: We have analyzed uterine leiomyomas and matching normal tissue for the expression of p14
Arf and
used explants to see if reducing the MDM2 activity using the small-molecule inhibitor nutlin-3 can induce p53 and
activate genes involved in senescence and/or apoptosis. For these studies quantitative real-time RT-PCR, Western
blots, and immunohistochemistry were used. Statistical analyses were performed using the student’s t test.
Results: An in depth analysis of 52 fibroids along with matching myometrium from 31 patients revealed in almost
all cases a higher expression of p14
Arf in the tumors than in the matching normal tissue. In tissue explants,
treatment with the MDM2 inhibitor nutlin-3 induced apoptosis as well as senescence as revealed by a dose-
dependent increase of the expression of BAX as well as of p21, respectively. Simultaneously, the expression of the
proliferation marker Ki-67 drastically decreased. Western-blot analysis identified an increase of the p53 level as the
most likely reason for the increased activity of its downstream markers BAX and p21. Because as a rule fibroids
express much higher levels of p14
Arf, a major negative regulator of MDM2, than matching myometrium it was then
analyzed if fibroids are more sensitive against nutlin-3 treatment than matching myometrium. We were able to
show that in most fibroids analyzed a higher sensibility than that of matching myometrium was noted with a
corresponding increase of the p53 immunopositivity of the fibroid samples compared to those from myometrium.
Conclusions: The results show that uterine fibroids represent a cell population of advanced cellular age compared
to matching myometrium. Moreover, the data point to members of the p53-network as to potential novel
therapeutic targets for the treatment of uterine fibroids.
Keywords: fibroids, p14
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Background
Uterine fibroids are by far the most common gynaecolo-
gical tumors at all. In premenopausal women incidences
of 60-70% have been reported [1,2] Although only a
minority of the leiomyomas become symptomatic the
presence of symptomatic leiomyomas is still the leading
cause for hysterectomy worldwide. Despite their high
prevalence the treatment options besides surgical
removal by hysterectomy or tumor enucleation are still
limited. Treatment by GnRH agonists as well as antago-
nists can induce shrinkage of fibroids but re-growth of
the tumors usually occurs after termination of the ther-
apy [3,4]. Thus, intervention at the hormonal level is as
a rule only recommended to reduce tumor size pre-
operatively [5]. Another alternative represents
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myoma-related symptoms is not a rare finding after that
treatment as well [6]. Thus, therapies aimed at perma-
nent shrinkage of the fibroids still remain a challenge.
Recently, we have presented evidence that in leiomyoma
development the overexpression of p14
Arf drives a nega-
tive feedback-loop between p53 and MDM2 that gov-
erns the fate of the individual fibroid. Compared to
matching myometrial tissue the myomas display a signif-
icantly higher expression of one of the genes of the
senescence associated Ink4a/Arf locus i.e. p14
Arf [7]. It is
not clear yet if this elevated expression solely results
from an enhanced proliferative activity of the fibroid
compared to its tissue of origin or if the same oncogenic
stimuli triggering the leiomyoma growth do simulta-
neously stimulate p14
Arf as an oncogene-induced senes-
cence-like mechanism. However, whatever is the cause
of the p14
Arf overexpression it activates a p53-MDM2
negative feedback-loop [8] that may govern a delicate
balance of the fibroids between proliferative activity and
senescence [7]. This makes antagonizing MDM2 an
interesting approach towards the growth control of
fibroids. Accordingly, we have used nutlin-3, a known
MDM2 inhibitor, to antagonize its activity in cell cul-
tures from fibroids. Interestingly, we were able to show
that antagonizing MDM2 induces the activity of genes
associated with senescence (p21)a sw e l la st h o s ew i t h
apoptosis (BAX) in leiomyoma cells in vitro [9]. Also,
the MDM2 inhibitor drastically reduced cell prolifera-
tion as indicated by a decreasing level of Ki-67 expres-
sion. Nevertheless, the question arises if fibroids display
a higher sensitivity than matching myometrium as can
be suggested from their higher expression of p14
Arf [7]
or the spontaneous senescence observed in fibroids [10].
Herein, we have used tissue explants taken from leio-
myomas and matching myometrium to analyze the
effects of an MDM2 antagonist and possible different
sensitivities of the fibroids and their matching tissue of
origin.
Methods
Tissue Samples
Altogether, tissue samples of 36 patients have been
investigated in this study (Table 1). The study was
approved by the local ethics committee (Ethikkomission
bei der Ärztekammer Bremen) and prior to surgery,
informed written consent was obtained from all patients.
For gene expression studies samples of 52 UL from 31
patients along with matching myometrium were taken
during surgery, immediately frozen in liquid nitrogen,
and stored at -80°C for RNA isolation and qRT-PCR
analyses of p14
Arf. For MDM2 inhibition six tissue sam-
ples of UL from four patients as well as matching
myometrium were taken during surgery and immedi-
ately transferred into sterile Hank’s solution.
Treatment by Nutlin-3
For treatment by nutlin-3 (Biomol, Hamburg, Germany)
tissue samples were minced into small pieces of
approximately 0.5 cm diameter and incubated in med-
ium 199 supplemented with 20% FCS and nutlin-3 (3,
10, or 50 μM) for 72 h. As controls tissue explants were
incubated in medium 199 supplemented with 20% FCS
without nutlin-3 for 72 h.
RNA Isolation
RNA isolation was performed using the RNeasy mini kit
(Qiagen, Hilden, Germany) and DNase I digestion was
performed following the manufacturer’s instruction.
cDNA-Synthesis
About 250 ng of total RNA were reverse transcribed
with 200 U/μl of M-MLV reverse transcriptase (Invitro-
gen, Karlsruhe, Germany), RNase Out, 150 ng random
hexamers and 10 mM dNTPs according to the manufac-
turer’s instructions. RNA was denatured at 65°C for 5
min and subsequently kept on ice for 1 min. After add-
ing the enzyme to the RNA primer mixes, samples were
incubated for 10 min at 25°C to allow annealing of the
random hexamers. Reverse transcription was performed
at 37°C for 50 min followed by inactivation of the
reverse transcriptase at 70°C for 15 min.
Quantitative Real-Time PCR (qRT-PCR)
Relative quantification of transcription levels was carried
out by real-time PCR analyses using the Applied Biosys-
tems 7300 real-time PCR system (Applied Biosystems,
Darmstadt, Germany). Commercially available gene
expression assays (Applied Biosystems, Darmstadt, Ger-
many) were used for quantification of mRNA of human
p14
Arf (Hs00924091), BAX (Hs00180269_m1), CDKN1A
(Hs99999142), MDM2 (Hs01066930_m1) and MKI67
(Hs00606991_m1). HPRT served as endogenous control
[7]. All qRT-PCR experiments were done in triplicate.
Cytogenetic and Molecular Cytogenetic Studies
Chromosome analyses and fluorescence in situ hybridi-
zation (FISH) were performed following routine techni-
ques as described previously [11].
Immunohistochemical studies of tissue explants
Immunohistochemical staining for p53 (clone DO-7,
DAKO, Glostrup, Denmark) as well as Ki-67 (clone
MIB-1, DAKO, Glostrup, Denmark) proteins was per-
formed using a detection kit (DAKO ChemMate,
DAKO, Glostrup, Denmark) and a semi-automated
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Page 2 of 11Table 1 Age of the patients, tumor size and karyotype of the leiomyomas investigated.
case
no.
Age tumor-size
[cm]
karyotype
0501-1 48 8.0 46, XX [36]
0503-1 40 4.0 46, XX, inv(5)(q15q31~33), t(12;14)(q15;q24)[13]
0504-1 43 2.0 46, XX [11]
0515-1 46 3.0 n.d.
0529-1 44 7.0 46, XX [12]
0529-2 44 5.0 46, XX [14]
0533-1 41 6.0 46, XX, r(1), t(1;12;14)(p36.3;q14;q24)[19]
0535-1 43 5.0 47, XX, +10 [2]/46, XX [10]
0535-2 43 4.0 46, XX, t(8;11)(p23;q13.1)[6]/47, XX, +12 [2]/46, XX [15]
0535-3 43 3.0 46, XX [7]
0535-4 43 2.0 46, XX [15]
0535-5 43 2.0 46, XX, del(7)(q11.2?)[2]/46, XX [12]
0538-4 36 3.0 46, XX [6]
0540-1 49 4.0 46, XX [10]
0540-2 49 N/A 46, XX [4]
0541-1 37 7.0 46, XX, t(12;14)(q15;q24)[5]/46, XX [9]
0545-1 47 5.0 46, XX, t(12;14)(q15;q24)[9]/46, XX [3]
0549-2 49 3.5 46, XX [10]
0549-3 49 4.0 46, XX [10]
0549-4 49 6.0 48, XX, +der(6), -8, +11, +mar [11]
0556-1 42 5.0 46, XX, t(3;5;12)(q25;p14;q15)[11]/45, XX, t(3;5;12)(q25;p14;q15), -22 [10]
0557-1 38 1.0 46, XX [10]
0561-1 44 15.0 n.d.
0579-1 49 1.5 46, XX, t(12;15;14)(q15;q26;q24)[20]
0583-1 40 5.5 46, XX [16]
0596-1 49 8.5 46, XX, ins(2;12)(q34 or q35;q24.3 or q24.1q13), inv(4)(q27q31.3)[22]
0628-1 57 4.0 46, XX, t(2;4)(q33;q25)[14]
0628-2 57 1.5 46, XX, ?ins(12;14)(q15;q31q24)[5]/46, XX [14]
0632-1 47 4.0 46, XX, t(12;14)(q15;q24)[12]/46, XX, del(4)(q31orq32), der(10), ?t(10;14)(q24;q32), t(12;14)(q15;q24)[9]
0635-1 48 N/A 46, XX, der (10), del(12)(q13 or q14) [18]
0643-1 52 1.0 n.d.
0643-2 52 6.0 46, XX, t(12;14)(q15;q24)[14]
0643-3 52 2.0 46, XX [12]
0646-1 47 9.5 46, XX, t(2;12)(p21;p13)[11]
0649-1 42 2.0 46, XX [14] remark: 46, XX, der(14)t(12;14) as single cell aberration
0653-1 50 1.0 46, XX [14]
0653-2 50 1.5 46, XX [15]
0653-3 50 2.5 46, XX [10]
0654-1 43 3.0 46, XX [8]
0654-2 43 2.3 47, XX, +12 [4]/46, XX [12]
0654-3 43 1.8 46, XX [14]
0668-1 57 3.0 46, XX [10]
0668-2 57 2.0 46, XX [11]
0668-3 57 2.5 46, XX [7]
0673-2 45 3.0 46, XX [13]
0681-1 48 7.5 45, XX, der(1)( ?)t(1;14)(p36.3;q24), der(1)del(1)(q32)?t(1;11)(p36.1;q13), del(3)(q26), add(6)(p21.3), -10, -11, del(12)(q24.1),
der(14)t(6;14)(p21.3;q24), add(19)(q13.4), +r [20]
0682-1 69 1.5 46, XX [16]
0682-2 69 1.0 46, XX [38]
Markowski et al. BMC Women?’?s Health 2012, 12:2
http://www.biomedcentral.com/1472-6874/12/2
Page 3 of 11stainer (DAKO TechMate, DAKO, Glostrup, Denmark)
according to the specifications of the manufacturer. For
antigen retrieval the slides were treated in a PT Link
module (DAKO, Glostrup, Denmark) using the EnVi-
sion™ FLEX Target Retrieval Solution, Low pH
(DAKO, Glostrup, Denmark). For both antibodies, the
dilution was 1:100.
Western Blot Analysis
Protein extracts were obtained using RIPA buffer and
concentrations were determined using a BCA protein
assay (Thermo Scientific, Rockford, USA) according to
the manufacturer’s instructions. Total protein (16 μg per
lane) was separated using a SDS-polyacrylamide gel and
transferred onto a nitrocellulose membrane. SeeBlue
Plus2 Pre-Stained Standard (Invitrogen, Karlsruhe, Ger-
many) was used as marker. The membranes were incu-
bated with primary anti-p53 (mouse, monoclonal, 1:200;
DAKO, Hamburg, Germany) and anti-beta-actin (rabbit,
p o l y c l o n a l ,1 : 7 ,5 0 0 ;S a n t aC r u z Biotechnology, Califor-
nia, USA) followed by incubation with the correspond-
ing secondary antibodies (alkaline phosphatase-
conjugated goat anti-mouse IgG (1:5, 000) (Invitrogen,
Karlsruhe, Germany) and alkaline phosphatase-conju-
gated bovine anti-rabbit IgG (1:3, 750) (Santa Cruz Bio-
technology, California, USA)). The bands were
visualized by incubating the membrane with NBT/BCIP
(Nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-
indolyl phosphate) (Roche Applied Science, Mannheim,
Germany) according to the manufacturer’si n s t r u c t i o n s .
Immunoblots were scanned using a flatbed scanner and
image analysis was performed with the ImageJ gel analy-
sis algorithm.
Statistical Analysis
The statistical significance of differences was assessed by
the student’s t test. In all comparisons, p < 0.05 was
considered being statistically significant and p < 0.01
was considered being highly significant. Individual
differences between the expressions in leiomyomas and
myometrium were tested by a pairwise t test, using
means of measurements within an individual if more
than one leiomyoma was analysed for that individual.
Results
Nutlin-3 induces senescence as well as apoptosis in tissue
explants from leiomyomas
To see if nutlin-3 can induce similar effects on the gene
expression of p21 and BAX as were recently observed
explants from a total of four leiomyomas (Table 1) were
incubated with nutlin-3 (3 μMa n d1 0μM each) for 72
h and then checked for the expression of these genes. In
addition, the expression of the proliferation marker Ki-
67 was analyzed. Compared to the controls the results
show concentration-dependent highly significant (p <
0.01 or p < 0.001, respectively) increases of the expres-
sion of p21 and BAX in all explants analyzed (Figure
1A, B) with both concentrations used. Accordingly, the
expression of Ki-67 strongly decreased except for one
case where with a concentration of 3 μM an increase of
Ki-67 expression was noted (Figure 1C).
Nutlin-3 increases the amount of p53 in a concentration-
dependent manner
Nutlin-3 acts as an inhibitor of MDM2 which in turn
destabilizes p53. To see if the increased expression of
the senescence and apoptotic markers that was noted
after treatment of the explants with nutlin-3 was indeed
due to an elevated level of p53 explants of case 0700-1
treated with 30 μMa n d5 0μM nutlin-3, respectively,
for 72 h were used for immunoblot analyses. The results
clearly show a concentration-dependent increase of p53
(Figure 2A, B).
Fibroids express significantly higher levels of p14
Arf than
matching myometrium
Previously, expression analysis of a series of UL and
eight myometrial samples revealed a significantly higher
Table 1 Age of the patients, tumor size and karyotype of the leiomyomas investigated. (Continued)
0683-1 47 6.0 46, XX, del(7)(q22q32)[5]/46, XX [3]
0683-2 47 1.0 46, XX [21]
0686-1 57 6.0 n.d.
0686-2 57 1.0 46, XX [20]
0686-3 57 1.0 46, XX [13]
0687-1 N/A 1.0 46, XX, der(10)add(10)(p)add(10)(q)[3]/46, XX [15]
0694-2 N/A 9.0 n.d.
0695-1
0695-2
0695-3
68
68
68
2.5
6.0
1.0
n.d.
n.d.
n.d.
0700-1 N/A 1.5 46, XX [11]
Karyotypes are described according to [20].
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Page 4 of 11Figure 1 Tissue explants taken from uterine fibroids show a nutlin-3 sensitivity as revealed by the increased expression of p21, BAX,
and decreased expression of Ki-67 mRNA after 72 h incubation with nutlin-3 compared to the controls. Expression in the control
explants (white bars, no treatment) was always set 100%. Ordinate: % change of expression compared to control. Hatched bars: 3 μM nutlin-3;
grey bars: 10 μM nutlin-3. For tumor numbers below each group of bars rf. to Table 1. A: p21, B: BAX, C: Ki-67. Statistically significant increases
(p21 and BAX) or decreases (Ki-67) are given by asterisks ( **, p < 0.01; ***, p < 0.001).
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Arf in the UL compared to their tissue
of origin [7]. Now, we have extended that smaller series
to a total of 52 fibroids and 31 matching myometrial tis-
sues. On average, the myometrial samples expressed 10-
fold lower levels of p14
Arf than the fibroids (1.14 vs.
11.5) (p < 0.001). Moreover, in all but two fibroids the
expression of p14
Arf in the fibroid taken from a patient
extended that of the corresponding myometrium (Figure
3A). Also, a marked heterogeneity of the expression
between the UL of individual patients was noted as well.
Because we were recently able to demonstrate that the
expression of p14
Arf is correlated with that of MDM2
[7] most likely resulting from a positive feedback-loop
driven by p53 we have also compared the expression of
MDM2 in fibroids and matching myometrium. In all
samples examined the expression of MDM2 in the
fibroids exceeded that found in the myometrium (Figure
3B). Furthermore, we were able to confirm the positive
correlation between the expression of p14
Arf and MDM2
(Figure 4) that was noted before on a smaller series of
cases including three myometrial tissues only [7].
As a rule leiomyomas show a higher sensitivity against
nutlin-3 treatment than matching myometrium
In an earlier paper we had been able to show that leio-
myomas show elevated levels of p14
Arf mRNA compared
to myometrium likely to result in an elevated level of
p53 which due to a negative feedback-loop between p53
and MDM2 in turn leads to an activation of MDM2 [7].
Furthermore, we had hypothesized that within the
p14
Arf-driven pathway a delicate balance between p53
and MDM2 assures the proliferative activity of leiomyo-
mas as well as their genomic integrity [12]. Accordingly,
it can be speculated that leiomyomas may be more sen-
sitive against MDM2 inhibition than matching myome-
trium. For the same cases used before and one
additional case (one leiomyoma plus matching myome-
trium; cf. Table 1) samples of myometrial tissue have
been treated with 3 μMa n d1 0μM nutlin-3 for 72 h to
analyze and compare the expression of p21, and BAX
with that of the matching leiomyomas. The expression
of p21 in the leiomyomas generally exceeded that found
in the myometrium with 3 μM nutlin-3 (211.93% vs.
100%; p < 0.01) and 10 μM nutlin-3 (150.84% vs. 100%;
p < 0.05). Moreover, in all three cases and with two
concentrations the expression of p21 in the explants
from the single fibroids exceeded that determined in the
matching myometrium Figure 5A, B). Likewise, the
expression of BAX in the tumors exceeded that seen in
the myometrium (3 μM nutlin-3: 145.37% vs. 100%; p <
0.001; 10 μM nutlin-3: 112.85% vs. 100%; n.s.). As to the
BAX expression of the single tumors a higher sensitivity
of the leiomyomas compared to their matching myome-
trium was noted except for two cases (683 and 687)
where with 10 μM the expression in the myometrium
slightly exceeded that of the leiomyoma (Figure 5C, D).
Except for the BAX expression of these latter two
explants and one other explant all individual differences
between any of the other explants and their matching
myometrium samples were found to be statistically sig-
nificant. In addition individual differences between the
expressions in leiomyomas and myometrium were tested
by a pairwise t test, using means of measurements
within an individual if more than one leiomyoma was
analyzed for that individual. This test procedure resulted
i nah i g h l ys i g n i f i c a n td i fference (p < 0.01) for the
expression of BAX and a borderline significance (p =
0.06866) for the expression of p21.
Nutlin-3 treatment induces an increasing amount of p53
Because MDM2 inhibition can be expected to raise the
level of p53 and it was shown that nutlin-3 treatment
increases the amount of p53 expressed by the explants
(c.f. Figure 2) we were interested to see if an IHC-scor-
ing system may also detect thec o m p a r a b l ed i f f e r e n c e s
between UL and matching myometrium as those shown
by qRT-PCR for the expression p21 and BAX.T r e a t -
ment of the explants by nutlin-3 caused a clearly
increased intensity of p53 staining which was concentra-
tion-dependent (Table 2). An example of the p53 stain-
ing patterns after IHC is given in Figure 6. Further
Figure 2 Western Blot analyses of explants treated with nutlin-
3 reveal a concentration dependent increase of the amount of
p53. A: Western Blot analysis of p53 of explants from an UL (case
700-1) treated with 30 μM and 50 μM nutlin-3 for 72 h shows a
concentration-dependent increase of the amount of p53. Lane 1:
marker SeeBlue Plus2 Pre-Stained Standard (Invitrogen, Karlsruhe,
Germany), lane 2: control without nultin-3, lane 3: 30 μM nutlin-3,
lane 4: 50 μM nutlin-3 (left to right). B: p53 protein expression
determined after immunoblotting (c.f. A) by ImageJ (as described in
the materials and methods section) against beta-actin. Control was
set 100%. Ordinate: % change of p53 expression compared to
control.
Markowski et al. BMC Women?’?s Health 2012, 12:2
http://www.biomedcentral.com/1472-6874/12/2
Page 6 of 11analyses showed an increased number of p53-positive
cells as well when comparing UL with matching myo-
metrium. In some of the samples IHC using Ki-67 was
performed as well. Whereas, corresponding to the litera-
ture [13], 1 - 2% positive cells were seen in the controls,
they were absent from any of the nutlin-3-treated
samples.
Uterine leiomyoma cells do not recover during long-term
inhibition of MDM2
T os e eh o wt h eg e n ee x p r e s s i o np a t t e r n sf o rp21, BAX,
and Ki-67 change after six days of MDM2 inhibition
and if the cells become resistant we have additionally
performed gene expression analyses for these genes on a
series of three UL along with matching myometrium
(Figure 7A-C). Akin to a shorter exposure to nutlin-3
the long term experiment did also significantly increase
the expression of p21 and BAX and decreased that of
Ki-67 in a dose-dependent manner. Furthermore, clear
Figure 3 Leiomyomas usually express higher levels of p14
Arf and MDM2 than matching myometrium. Columns within each row give the
relative expression of p14
Arf mRNA (A) and MDM2 mRNA (B) in myometrium (violett columns) and matching fibroids (blue columns) from one
patient each as revealed by qRT-PCR. Number below each row corresponds to the patient’s lab no. The corresponding leiomyomas are depicted
in a numerical order (cf. Table 1). Ordinates gives relative expression of p14
Arf and MDM2, respectively.
Figure 4 Highly significant (p < 0.001) correlation between the
MDM2 expression (x-axis) and the p19
Arf expression (y-axis) in
myometrium (white boxes) and leiomyoma tissues (violet
circles). One myometrial tissue served as calibrator (expression: 1).
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matching fibroids became apparent that again point to a
reduced sensitivity of the myometrium against the
MDM2 inhibition.
Discussion
Recently, we have shown that compared to myometrium
leiomyomas express higher levels of p14
Arf, an important
upstream regulator of p53 [7]. Herein, this observation
has been confirmed on a much larger series of cases. In
addition, a marked heterogeneity of the p14
Arf expression
was noted when comparing UL from one patient. Most
likely due to the well-documented positive feedback-loop
that exists between p53 and MDM2 [14,15], the fibroids
do also express higher levels of MDM2 leading to a posi-
tive correlation between p14
Arf and MDM2 expression
[7] that may keep fibroids in a delicate balance between
growth and senescence. This finding has been confirmed
here based on a larger series and makes MDM2 an inter-
esting target molecule for the growth control of leiomyo-
mas. Accordingly, we were able to demonstrate that in
leiomyoma cells in vitro treatment with nutlin-3, a small-
molecule inhibitor of MDM2, activates the expression of
canonical groups of genes associated with senescence
and apoptosis downstream of p53 [9]. Herein, we were
able to show that as a rule tissue explants taken from
leiomyomas display a higher sensitivity after treatment
with nutlin-3 than do those from matching myometrium.
Of note, nutlin-3 increased the expression of p53-depen-
dent marker genes associated with senescence as well as
with apoptosis. As a rule for both genes i.e. p21 and BAX
leiomyoma tissue turned out to be more sensitive than
myometrial tissue. We assume that the higher expression
of p14
Arf in the fibroids [7] is the most likely explanation
for this different sensitivity. When interpreting leiomyo-
mas as the result of proliferation of a stem-cell like popu-
lation it seems reasonable to assume that this
proliferation is accompanied by activation of the p53-
pathway via p14
Arf to protect the cellular genome [12].
Vice versa, functional p53 activates the positive feedback-
loop with MDM2 that may be essential for the develop-
ment of fibroids. Likewise, disturbing this balance by
MDM2 inhibitors can be assumed to cause senescence as
well as apoptosis of the leiomyoma cell population
because p53 still remains intact with a strongly decreased
MDM2 activity.
The present study has limitations which are mainly
related to the use of an in vitro model. Cell cultures
Figure 5 As a rule fibroids display a higher nutlin-3 sensitivity than matching myometrium. Explants from five fibroids from three patients
were checked for their nutlin-3 sensitivity after incubation with 3 μMo r1 0μM nutlin-3 respectively, for 72 hours. As an indicator for sensitivity
the expression of BAX (A, B) and p21 (C, D) mRNA was determined by qRT-PCR. Myometrium (violet columns) was always set 100% and the
expression of the corresponding fibroids (light blue columns) refers to that value. Numbers below each row indicate the patient’s lab no. (cf.
Table 1). The corresponding leiomyomas are depicted in numerical order. Statistically significances are given by asterisks (*, p < 0.05; **, p < 0.01;
***, p < 0.001).
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Page 8 of 11Table 2 Treatment by nutlin-3 results in a concentration dependent increase of the number of p53 positive cells as
well as of the staining intensity as revealed by immunohistochemistry.
#case treatment duration of treatment number of p53-positive cells intensity percentage of Ki67-positive cells
0694-2 control 11 0 - 1 n.d.
10 μM nutlin-3 72 h 393 2 n.d.
30 μM nutlin-3 1, 277 3 n.d.
0695-0 control 0 0 4%
10 μM nutlin-3 11 1 < 1%
30 μM nutlin-3 188 1 < 1%
0695-1 control 0 0 -
10 μM nutlin-3 42 0 - 1 -
30 μM nutlin-3 6 days 89 1 -
0695-2 control 0 0 < 1%
10 μM nutlin-3 194 1 - 2 -
30 μM nutlin-3 799 3 -
0695-3 control 0 0 < 1%
10 μM nutlin-3 770 3
30 μM nutlin-3 1, 493 3
0687-0 control 0 0 n.d.
10 μM nutlin-3 2 1 n.d.
30 μM nutlin-3 72 h 257 2 n.d.
0687-1 control 0 0 n.d.
10 μM nutlin-3 398 2 n.d.
30 μM nutlin-3 n.d. n.d. n.d.
For further information of the tumors studied (karyotype, age, tumor size) see Table 1.
Figure 6 Immunohistochemistry reveals that nutlin-3 causes a dose-dependent increase of p53 in fibroids exceeding that in
myometrium. A: leiomyoma 695-3, control without nutlin-3; B. myometrium 695-0, control without nutlin-3; C: leiomyoma 695-3 after 6 days
exposure to 10 μM nutlin-3; C: myometrium 695-0 after 6 days exposure to 10 μM nutlin-3.
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Page 9 of 11from fibroids can easily be set up without major pro-
blems of overgrowing of normal cells but the cells have
only a limited growth potential and, as an even more
serious reason for concern, rapidly lose characteristic
features of leiomyomas in vivo. E.g. the estrogen recep-
tor level of fibroid cells rapidly declines in vitro [16].
Immortalization of the cells is possible e.g. by using
SV40-large T-antigen or the SV40 early region, but with
these cells experiments are still facing the problem of
drastic changes compared to the normal cells [17].
Though the explants cultures as used here may reflect
the in vivo situation better than isolated cells it is well
known that explant cultures as well loose characteristics
o ft h et i s s u ei nv i v oe . g .ad e c r e a s et h ee x p r e s s i o no f
estrogen receptors after a short time in vitro has been
noted [18] that was within the time-range used here for
the nutlin-3 experiments. Nevertheless, the higher sensi-
tivity of the leiomyoma tissue against the inhibition of
MDM2 compared to surrounding myometrium corre-
sponds to a higher in vivo expression of p14
Arf and thus
likely exists in vivo as well. Then, it may have consider-
able therapeutical implications. In UL antagonizing
MDM2 seems to be a way to induce growth arrest as
well as apoptosis. Both can be expected to irreversibly
impair tumor growth and to decrease the tumor size,
respectively. Interestingly, estrogens are known as nega-
tive regulators of p53 [19]. Thus, it seems reasonable to
speculate that changes of the behaviour of fibroids fol-
lowing changes of the hormonal milieu as in particular
their shrinkage are at least in part also due to skewing
the balance towards p53. Accordingly, a combination e.
g. of a GnRH antagonist and a MDM2 antagonist may
be a favourable approach for the treatment of fibroids.
In summary, the results of the present study strengthen
the idea that senescence and apoptosis play an impor-
tant role in the growth control of fibroids and that their
induction may offer interesting approaches for the ther-
apy of these frequent tumors.
Conclusions
Based on their expression of p14
Arf we have concluded
that as a rule leiomyomas represent a cell population of
advanced senescence compared to matching myometrial
tissue. Accordingly, fostering the p14
Arf -p 5 3n e t w o r k
by nutlin-3, a known MDM2 antagonist, increases the
expression of pro-senescence and pro-apoptotic genes in
t i s s u ee x p l a n t sf r o mm y o m e t r i u ma sw e l la sf r o ml e i o -
myomas with the latter displaying a significantly higher
sensitivity than the matching normal tissue. In summary,
though the data need confirmation in vivo they point to
members of the p53-network as to potential novel thera-
peutic targets for the treatment of uterine fibroids.
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